I have been working on the full-length synthetic HIV-1 Tat protein for many years and originally performed in 1997 the full structure activity relationship study which highlighted the cationic region of the protein to be responsible for the cellular translocation property. One of the first Cell-Penetrating Peptide was identified. This Tat peptide has been then exploited worldwide for the cellular delivery of hundreds of different molecules (proteins, peptides, nucleic acids, liposomes, nanoparticles…). Later in 2003, I further investigated the mechanism of cell entry of this peptide and discovered that artefactual fixation conditions altered the pattern of the experimental data previously presented for this category of cell-penetrating peptide. Few years ago, I oriented my research in the design of original cancer cell-targeting peptides in order to deliver any devices loaded with drugs or pharmaceutical molecules specifically to the tumour cells. Five years ago, I joined the research group of Prisca Boisguérin, Karidia Konate, Sébastien Deshayes. Based on our respective expertise, we designed with Gudrun Aldrian a large series of new Cell-Penetrating Peptides and we discovered the impressive ability of the WRAP peptides to promote the cellular delivery of various nucleic acid molecules.
My research topics are focused on the design, the synthesis and the development of peptides, focused especially on the Cell-Penetrating Peptides (CPPs), but also on peptides aimed to interfere with various biological activities.
Fields of interest
Peptide Design and Chemistry, Cell Uptake, Biological Effects.
Peptide synthesis and purification, Peptides labeling and modifications, Biological evaluation of peptides.
Cell-penetrating peptides, Cell delivery, Peptide Interferences
Several publicationsKonate K.; Josse E.; Tasic M.; Redjatti K.; Aldrian G.; Deshayes S.; Boisguérin P.; Vivès E. “WRAP-based nanoparticles for siRNA delivery: A SAR study and a comparison with lipid-based transfection reagents”. 2021. Submitted for publication in Journal of NanoBiotechnology.
Deshayes S., Konate K., Vivès E. and Boisguérin P. “WRAP-Based Nanoparticles: a potent siRNA Delivery System using Direct Membrane Translocation”. 2021. Chapter in Springer Nature Sciences Book (Springer Edition), Methods in Molecular Biology. In press.
Konate K., Seisel Q., Vivès E., Boisguérin P., Deshayes S., “Fluorescent Leakage Assay to Investigate Membrane Destabilization by Cell-Penetrating Peptide” 2020, J.Vis.Exp. (JoVE) (166), doi:10.3791/62028 (2020).
Deshayes S, Konate K, Dussot M, Chavey B, Vaissière A, Nhu Ngoc Van T., Aldrian G, Padari K, Pooga M., Vivès E., Boisguérin P., “Deciphering the internalization mechanism of WRAP:siRNA nanoparticles”, Biochimica et Biophysica Acta (BBA) - Biomembranes, 2020, Volume 1862, (6), 183252.
Konate K., Dussot M., Aldrian G., Vaissière A., Viguier I, Ferreiro Neira I., Couillaud F., Vivès E., Boisguerin P., Deshayes S. «Peptide-based nanoparticles to rapidly and efficiently “Wrap’n Roll" siRNA into cells ». 2019, Bioconjugate Chemistry, vol 30, Issue 3, 592-603.
Aldrian G., Vaissière A., Konate K., Seisel Q., Vivès E., Fernandez F., Viguier V., Genevois C., Couillaud F., Démèné H., Aggad D., Covinhes A., Barrère-Lemaire S., Deshayes S., Boisguerin P. «PEGylation rate influences peptide-based nanoparticles mediated siRNA delivery in vitro and in vivo». 2017. J. Control. Release, 256, 79-91.
Vivès E., Brodin P. and Lebleu B. "A truncated version of the HIV-1 Tat basic peptide translocates efficiently through the plasma membrane and accumulates in the nucleus." 1997. J. Biol. Chem, 272, 16010-16017.
Schmidt J., Garambois V., Rocheblave L., Martinez J., Pèlegrin A., Cavelier F. and Vivès E. “Cyclization of peptides through an urea bond: application to the Arg-Gly-Asp tripeptide” 2010, ChemBioChem, 11 (8), 1083-1092.
Brooks, H, Lebleu B. and Vivès E. "Tat mediated transduction: Back to basics." 2005. Adv. Drug Deliv. Rev., 57, 559-577.
Vivès E. “Present and future of peptide-mediated delivery systems. Is the Trojan horse too wild to go only to Troy?” 2005, Journal of Controlled Released 109 (1-3), 77-85.